Posted On: 12/07/2014 9:47:09 AM
Post# of 94314
$BMY Recent News
4 stocks to watch 1:44 p.m. Nov. 19, 2014 - The Trading Deck
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Charting a bullish post-election backdrop 11:05 a.m. Nov. 5, 2014 - Michael Ashbaugh
6 stocks to watch 1:35 p.m. Oct. 29, 2014 - The Trading Deck
Updates, advisories and surprises 11:31 a.m. Oct. 24, 2014 - MarketWatch
Amazon, Pandora sink in wake of results; KLA-Tencor surges 9:49 a.m. Oct. 24, 2014 - Sue Chang
Bristol-Myers profit slips, but tops expectations 6:45 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers sees 2014 total sales $15.2 bln-$15.8 bln vs. FactSet consensus $15.58 bln 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers lowers 2014 net EPS outlook to $1.15-$1.25 from $1.50-$1.60 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers affirms 2014 adj. EPS outlook of $1.70-$1.80 6:34 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 FactSet sales consensus $3.81 bln 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 sales $3.92 bln vs. $4.07 bln a year ago 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 adj. EPS 45 cents vs. FactSet consensus 42 cents 6:32 a.m. Oct. 24, 2014 - Tomi Kilgore
Mead Johnson Nutrition profit rises 9.5% 7:21 a.m. Oct. 23, 2014 - MarketWatch.com
More than 1/3 of Dow stocks to report this week 4:31 a.m. Oct. 19, 2014 - Wallace Witkowski
Bristol-Myers drops Hepatitis C dual regimen in U.S. 10:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
FDA approves Merck's new-kind of cancer drug 1:58 p.m. Sept. 4, 2014 - MarketWatch.com
5 companies that will benefit from ALS awareness 6:58 a.m. Aug. 22, 2014 - Jennifer Booton
Glaxo chief faces increasing pressure: WSJ 5:29 p.m. Aug. 11, 2014 - MarketWatch.com
Bristol-Myers adjusted profit beats expectations 7:24 a.m. July 24, 2014 - MarketWatch.com
InsiderInsights.com Daily Round Up 12/5/14: HEES, CCC, CUDA, SC 3:27 a.m. Today - Seeking Alpha
Two Cancer Drugs Shown Effective 1:09 p.m. Dec. 6, 2014 - The Wall Street Journal Interactive Edition
Merck, Bristol Immunotherapies Expand Strongly Into Blood Cancers 1:00 p.m. Dec. 6, 2014 - TheStreet.com
Seattle Genetics Makes Case for Expanded Use of Adcetris as Lymphoma Maintenance Therapy 11:00 a.m. Dec. 6, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks 8:31 p.m. Dec. 4, 2014 - TheStreet.com
Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review 3:57 p.m. Dec. 4, 2014 - Seeking Alpha
Cancer’s Super-Survivors 1:46 p.m. Dec. 4, 2014 - The Wall Street Journal Interactive Edition
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14) 6:04 a.m. Dec. 4, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now 8:36 p.m. Dec. 3, 2014 - TheStreet.com
Avanir Stock Jumps On $3.5 Billion Otsuka Buyout 10:22 a.m. Dec. 2, 2014 - Investors Business Daily
Retirement Portfolio For Dummies - The Health Care Components 1:42 p.m. Nov. 30, 2014 - Seeking Alpha
Vargatef cleared in Europe for lung cancer 9:23 a.m. Nov. 28, 2014 - Seeking Alpha
FDA Seeks More Data on Bristol-Myers Hepatitis C Therapy 12:17 p.m. Nov. 26, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers gets CRL for daclatasvir NDA 11:51 a.m. Nov. 26, 2014 - Seeking Alpha
December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey 6:00 a.m. Nov. 26, 2014 - TheStreet.com
Drug makers face pushback on pricey meds 8:18 a.m. Nov. 25, 2014 - Seeking Alpha
Bristol-Myers and Five Prime team up in cancer 9:29 a.m. Nov. 24, 2014 - Seeking Alpha
Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen 12:21 p.m. Nov. 21, 2014 - Seeking Alpha
European Ad Comm gives thumbs up to AbbVie's HCV combo 8:48 a.m. Nov. 21, 2014 - Seeking Alpha
3 Best Vanguard Funds With Active Management 5:30 a.m. Nov. 21, 2014 - InvestorPlace.com
Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma 1:00 p.m. Dec. 6, 2014 - BusinessWire - BZX
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Millionin New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries 9:01 a.m. Dec. 1, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C 11:34 a.m. Nov. 26, 2014 - BusinessWire - BZX
Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 8:24 p.m. Nov. 24, 2014 - PR Newswire - PRF
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types 8:59 a.m. Nov. 24, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types 8:59 a.m. Nov. 24, 2014 - GlobeNewswire
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA) 8:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial 3:45 a.m. Nov. 16, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting 8:36 a.m. Nov. 12, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Foundation Awards $2 Million in New Grantsto Help Veterans and their Families Transition from Military to Civilian Life 9:00 a.m. Nov. 10, 2014 - BusinessWire - BZX
Upcoming Conferences, Contract Award, Quarterly Financial Results, and Completion of Acquisition - Research Reports on Bristol-Myers Squibb, 3M, Colony Financial, NOV and PPG 8:40 a.m. Nov. 10, 2014 - PR Newswire - PRF
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives the LEAD Award from The US Oncology Network 10:33 a.m. Nov. 7, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors 8:35 a.m. Nov. 5, 2014 - PR Newswire - PRF
Lexicon Strengthens Clincial Operations And Commercial Readiness 4:15 p.m. Nov. 4, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference 10:00 a.m. Nov. 4, 2014 - BusinessWire - BZX
Insider Trading Research for Micron, Bristol-Myers Squibb, Twitter, American Realty Capital Properties, Plug Power, and GoPro 8:45 a.m. Nov. 3, 2014 - PR Newswire - PRF
4 stocks to watch 1:44 p.m. Nov. 19, 2014 - The Trading Deck
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Charting a bullish post-election backdrop 11:05 a.m. Nov. 5, 2014 - Michael Ashbaugh
6 stocks to watch 1:35 p.m. Oct. 29, 2014 - The Trading Deck
Updates, advisories and surprises 11:31 a.m. Oct. 24, 2014 - MarketWatch
Amazon, Pandora sink in wake of results; KLA-Tencor surges 9:49 a.m. Oct. 24, 2014 - Sue Chang
Bristol-Myers profit slips, but tops expectations 6:45 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers sees 2014 total sales $15.2 bln-$15.8 bln vs. FactSet consensus $15.58 bln 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers lowers 2014 net EPS outlook to $1.15-$1.25 from $1.50-$1.60 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers affirms 2014 adj. EPS outlook of $1.70-$1.80 6:34 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 FactSet sales consensus $3.81 bln 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 sales $3.92 bln vs. $4.07 bln a year ago 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 adj. EPS 45 cents vs. FactSet consensus 42 cents 6:32 a.m. Oct. 24, 2014 - Tomi Kilgore
Mead Johnson Nutrition profit rises 9.5% 7:21 a.m. Oct. 23, 2014 - MarketWatch.com
More than 1/3 of Dow stocks to report this week 4:31 a.m. Oct. 19, 2014 - Wallace Witkowski
Bristol-Myers drops Hepatitis C dual regimen in U.S. 10:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
FDA approves Merck's new-kind of cancer drug 1:58 p.m. Sept. 4, 2014 - MarketWatch.com
5 companies that will benefit from ALS awareness 6:58 a.m. Aug. 22, 2014 - Jennifer Booton
Glaxo chief faces increasing pressure: WSJ 5:29 p.m. Aug. 11, 2014 - MarketWatch.com
Bristol-Myers adjusted profit beats expectations 7:24 a.m. July 24, 2014 - MarketWatch.com
InsiderInsights.com Daily Round Up 12/5/14: HEES, CCC, CUDA, SC 3:27 a.m. Today - Seeking Alpha
Two Cancer Drugs Shown Effective 1:09 p.m. Dec. 6, 2014 - The Wall Street Journal Interactive Edition
Merck, Bristol Immunotherapies Expand Strongly Into Blood Cancers 1:00 p.m. Dec. 6, 2014 - TheStreet.com
Seattle Genetics Makes Case for Expanded Use of Adcetris as Lymphoma Maintenance Therapy 11:00 a.m. Dec. 6, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks 8:31 p.m. Dec. 4, 2014 - TheStreet.com
Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review 3:57 p.m. Dec. 4, 2014 - Seeking Alpha
Cancer’s Super-Survivors 1:46 p.m. Dec. 4, 2014 - The Wall Street Journal Interactive Edition
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14) 6:04 a.m. Dec. 4, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now 8:36 p.m. Dec. 3, 2014 - TheStreet.com
Avanir Stock Jumps On $3.5 Billion Otsuka Buyout 10:22 a.m. Dec. 2, 2014 - Investors Business Daily
Retirement Portfolio For Dummies - The Health Care Components 1:42 p.m. Nov. 30, 2014 - Seeking Alpha
Vargatef cleared in Europe for lung cancer 9:23 a.m. Nov. 28, 2014 - Seeking Alpha
FDA Seeks More Data on Bristol-Myers Hepatitis C Therapy 12:17 p.m. Nov. 26, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers gets CRL for daclatasvir NDA 11:51 a.m. Nov. 26, 2014 - Seeking Alpha
December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey 6:00 a.m. Nov. 26, 2014 - TheStreet.com
Drug makers face pushback on pricey meds 8:18 a.m. Nov. 25, 2014 - Seeking Alpha
Bristol-Myers and Five Prime team up in cancer 9:29 a.m. Nov. 24, 2014 - Seeking Alpha
Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen 12:21 p.m. Nov. 21, 2014 - Seeking Alpha
European Ad Comm gives thumbs up to AbbVie's HCV combo 8:48 a.m. Nov. 21, 2014 - Seeking Alpha
3 Best Vanguard Funds With Active Management 5:30 a.m. Nov. 21, 2014 - InvestorPlace.com
Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma 1:00 p.m. Dec. 6, 2014 - BusinessWire - BZX
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Millionin New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries 9:01 a.m. Dec. 1, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C 11:34 a.m. Nov. 26, 2014 - BusinessWire - BZX
Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 8:24 p.m. Nov. 24, 2014 - PR Newswire - PRF
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types 8:59 a.m. Nov. 24, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types 8:59 a.m. Nov. 24, 2014 - GlobeNewswire
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA) 8:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial 3:45 a.m. Nov. 16, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting 8:36 a.m. Nov. 12, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Foundation Awards $2 Million in New Grantsto Help Veterans and their Families Transition from Military to Civilian Life 9:00 a.m. Nov. 10, 2014 - BusinessWire - BZX
Upcoming Conferences, Contract Award, Quarterly Financial Results, and Completion of Acquisition - Research Reports on Bristol-Myers Squibb, 3M, Colony Financial, NOV and PPG 8:40 a.m. Nov. 10, 2014 - PR Newswire - PRF
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives the LEAD Award from The US Oncology Network 10:33 a.m. Nov. 7, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors 8:35 a.m. Nov. 5, 2014 - PR Newswire - PRF
Lexicon Strengthens Clincial Operations And Commercial Readiness 4:15 p.m. Nov. 4, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference 10:00 a.m. Nov. 4, 2014 - BusinessWire - BZX
Insider Trading Research for Micron, Bristol-Myers Squibb, Twitter, American Realty Capital Properties, Plug Power, and GoPro 8:45 a.m. Nov. 3, 2014 - PR Newswire - PRF
(0)
(0)
